Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease.
Jinnie J RheeJialin HanMaria E Montez-RathSun H KimMark R CullenRandall S StaffordWolfgang C WinkelmayerGlenn M ChertowPublished in: Diabetes, obesity & metabolism (2022)
Incident prescription of SGLT-2 inhibitors was associated with lower risks of HF hospitalization but not with non-fatal MI or stroke despite suggesting benefit, relative to prescription of DPP-4 inhibitor across different stages of CKD.